Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.
Samir A BallestasJulio Hidalgo LopezAdam M KleinConor SteuerDong M ShinMarin AbousaudNicole C SchmittYong TengNabil F SabaAndrew T TkaczukPublished in: The Laryngoscope (2023)
Parenteral bevacizumab remains a well-tolerated treatment for patients with recalcitrant RRP. There appears to be a durable reduction in the frequency of debulking surgery requirements although on a maintenance regimen. Laryngoscope, 2023.